BPC-157 vs TB-500: Key Differences and Research Evidence (2026)
Reviewed by Oscar Reyes, PhD, Synthesis Lead at Apexion BioLabs · Scientific review of the chemistry and analytical content
Quick answer
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid synthetic peptide studied mainly in angiogenesis and tendon models. TB-500 is a seven-residue fragment of thymosin beta-4 (Ac-LKKTETQ) studied for actin regulation and cell migration. Both rely almost entirely on animal and cell data, and both are sold in the UK for laboratory research only.
- 15 amino acids vs a 7-residue thymosin beta-4 fragment
- Only one head-to-head study (rats, 2026): the combined “Wolverine stack” gave no extra benefit
- Both are unlicensed in the UK and on the WADA 2026 Prohibited List
Apexion supplies BPC-157 and TB-500 research pens, with batch details on each product page.
BPC-157 vs TB-500 compares two short synthetic peptides that keep turning up in the same tissue-remodelling research. BPC-157 is a 15-amino-acid partial sequence of a larger, naturally occurring protein. TB-500 is a seven-residue fragment of thymosin beta-4, a 43-amino-acid protein found in most mammalian cells. Both are sold in the UK for laboratory research only.
People compare them because both appear in angiogenesis, cell-migration and tendon models, and because online sources pair them as the “Wolverine stack”. The data behind that pairing is thin. In a 2026 head-to-head rat study, the two peptides combined did no better than either one alone (Biçer et al., 2026).
We’ve built this guide as an evidence ledger. Every finding is tagged by type: cell study, animal study, or human data with the number of people involved. That way you can see exactly how much weight each claim can carry.
Research use only: all compounds discussed here are supplied strictly for laboratory research and are not intended for human or veterinary use. Read our research use notice.
BPC-157 vs TB-500 at a Glance
BPC-157 and TB-500 differ in origin, size and research focus. BPC-157 is a 15-amino-acid sequence studied mostly in angiogenesis and tendon models. TB-500 is a seven-residue thymosin beta-4 fragment linked to actin and cell migration. Both rest almost entirely on animal and cell data, and both sit on the WADA Prohibited List.
| Research factor | BPC-157 | TB-500 |
|---|---|---|
| Basic identity | Synthetic pentadecapeptide, 15 amino acids | Synthetic fragment of thymosin beta-4 (Ac-LKKTETQ, 7 residues) |
| Main research themes | Angiogenesis, tendon and musculoskeletal tissue models | Actin dynamics, cell migration, collagen organisation |
| Evidence base | 35 of 36 studies in a 2025 review were preclinical | Fragment data is animal-only; human trials used full thymosin beta-4 |
| Human data | One retrospective chart review (12 people) and a two-person pilot | None for the fragment itself |
| Combination (blend) studies | One rat study (2026): no added benefit from combining | Same study |
| UK status | Unlicensed; not an MHRA-authorised medicine | Unlicensed; not an MHRA-authorised medicine |
| WADA status (2026) | Named under S0, non-approved substances | Listed under S2 as a thymosin beta-4 derivative |
| Documentation priority | Identity, purity, lot number, storage history | Identity, exact fragment sequence, purity, lot number |
“Which is better?” only makes sense against a defined model and endpoint. In the single study that tested both side by side, TB-500 was the only arm to reach a statistically significant gain in tendon strength over controls.
What Is BPC-157?
Molecular identity and nomenclature
BPC-157 stands for Body Protection Compound 157. It’s a synthetic pentadecapeptide, which simply means a chain of 15 amino acids. The name comes from early research that described the sequence as a partial fragment of a larger, naturally occurring protein. “Body protection” is a historical label from that literature. It makes no claim about what the peptide does.
Because the name says nothing about the material in the vial or pen, identity has to come from documentation. Our BPC-157 research material is supplied with a batch-specific Certificate of Analysis that you can match to the unit you receive.
Research themes in the literature
A 2025 systematic review in the HSS Journal grouped BPC-157 findings into a handful of themes. Each one carries its study type:
- Tendon and musculoskeletal tissue models (animal). In preclinical models, BPC-157 changed functional, structural and biomechanical measures.
- Growth-hormone receptor expression (in vitro). A 2014 study in rat tendon cells reported higher receptor expression that rose with dose and time (Chang et al., see References).
- Angiogenesis and cell-growth pathways (animal and in vitro). Studies report activity in angiogenesis (new blood-vessel formation) pathways.
- Inflammatory signalling (animal). Studies report lower levels of inflammatory cytokines, the signalling proteins cells use to coordinate inflammation.
Evidence limitations for BPC-157
The HSS Journal review screened 544 articles published between 1993 and 2024. It included 36 studies: 35 preclinical and one clinical, a retrospective chart review of 12 people. The authors reported that “no clinical safety data were found.” Almost everything said about BPC-157 traces back to rodents and cell cultures.
What Is TB-500?
TB-500 vs thymosin beta-4: not the same thing
Thymosin beta-4 (Tβ4) is a natural 43-amino-acid protein present in most mammalian cells, where it helps control actin, the protein that gives cells their shape and lets them move. TB-500 is a synthetic fragment usually described as the acetylated sequence Ac-LKKTETQ. That’s residues 17 to 23 of Tβ4, the region tied to actin binding.
The two are linked but separate materials. A seven-residue fragment and a 43-residue protein differ in size, structure and how fast they break down. So a finding for full-length Tβ4 isn’t automatically a finding for TB-500. Check that the fragment sequence on your COA matches the specification, because the label “TB-500” alone doesn’t confirm what’s inside.
Figure 1: BPC-157 (15 amino acids) vs TB-500 (Ac-LKKTETQ, residues 17 to 23 of thymosin beta-4).
Research themes associated with TB-500
TB-500 research centres on actin regulation, cell migration and tissue remodelling, themes inherited from Tβ4 biology. The fragment now has its own tendon data. In the 2026 rat Achilles study by Biçer and colleagues, the TB-500 group showed higher maximum load to failure than controls (p < 0.05) and significantly better Bonar histology scores (p = 0.016). Sirius red staining in that group also showed more organised type I collagen.
Our TB-500 research material lists its batch record on the product page.
Evidence limitations for TB-500
We sort TB-500 evidence into three buckets and keep them apart. Bucket one is fragment-specific work, which so far is animal-only. Bucket two is full-length Tβ4 research, which includes phase 1 and phase 2 human trials. Bucket three is general mechanism work on actin and migration. Most TB-500 marketing borrows from bucket two, and that data was generated with a different molecule.
BPC-157 vs TB-500: Key Differences
BPC-157 and TB-500 differ in sequence length, parent protein and the biology researchers study. BPC-157 is a 15-residue peptide explored in angiogenesis and growth-factor pathways. TB-500 is a seven-residue Tβ4 fragment explored in actin regulation and cell migration. Their evidence bases also differ, and only one study has compared them directly.
Molecular and structural differences
BPC-157 has 15 amino acids. TB-500 has seven, with an acetyl group capping its starting end. Their parent proteins are unrelated: BPC-157 is a partial sequence of a larger natural protein, while TB-500 is a partial sequence of the cytoskeletal regulator Tβ4. The HSS Journal review reports that BPC-157 has a half-life under 30 minutes in the studies reviewed, so it breaks down quickly.
Mechanisms explored in research
BPC-157 work focuses on blood-vessel formation, growth-hormone receptor expression and cytokine signalling. TB-500 work focuses on how cells build and move their actin scaffolding, plus collagen maturation in remodelling tissue. Both end up in “tissue remodelling” headlines, but they reach that label through different biology. The 2026 Biçer study hints at that difference at the tissue level. Collagen type I levels didn’t differ between groups, while collagen type III levels did, with the TB-500 group showing the clearest signs of matrix maturation.
Local vs Systemic: What the Research Says
Online content often frames BPC-157 as “local” and TB-500 as “systemic”. That split comes from the biology each one is tied to: BPC-157 from a single source protein, and TB-500 from Tβ4, which most cells contain. We found no published study that measured tissue distribution for the two side by side. The one direct comparison tested both peptides under identical conditions in the same tendon model, and both changed tendon tissue. Treat “local vs systemic” as a hypothesis that still needs testing.
Shared themes, different evidence
Both peptides appear in angiogenesis, inflammation and remodelling discussions, so they get filed together. A shared label hides big gaps in evidence quality, and it can make two very different literatures look interchangeable. BPC-157 has dozens of animal papers, while TB-500-specific data is far smaller. If you’re mapping other peptides studied in inflammation models, our KPV peptide guide covers a third compound that often appears in the same searches.
What Does the Evidence Actually Show?
Neither BPC-157 nor TB-500 has controlled human efficacy data. BPC-157’s evidence is 35 preclinical studies plus one retrospective chart review. TB-500’s fragment data is animal-only, while its parent protein, thymosin beta-4, has phase 1 and phase 2 human trials. Both sit near the base of the evidence hierarchy.
Evidence hierarchy
From strongest to weakest:
- Regulatory approval
- Large controlled human trials
- Small pilot or observational human studies
- Animal models
- Cell (in vitro) and mechanism studies
Figure 2: The evidence hierarchy, and where BPC-157 and TB-500 actually sit.
BPC-157 evidence profile (HSS Journal 2025 review, 35 of 36 studies preclinical)
Of the 36 studies the HSS Journal review included, 35 were preclinical. The one clinical paper was a retrospective review of 12 people, with no control group. The authors call the whole body of work “level IV and level V studies”, the two lowest tiers in clinical evidence grading.
TB-500 and thymosin beta-4 evidence profile
Thymosin beta-4 reached a phase 2 trial, registered on ClinicalTrials.gov (see References). That trial used the full 43-residue protein. Phase 1 safety work in healthy volunteers also used the full recombinant protein. For the TB-500 fragment, the published record we could find is animal work such as the 2026 Biçer study.
What researchers cannot conclude
A preclinical signal isn’t a human outcome. Neither peptide has a proven effect in people, and a rat tendon result says nothing about any other tissue or species. Any claim should name its model, its endpoint and its evidence tier. Even the strongest TB-500 result so far comes with a caveat from its own authors, who call their findings preliminary and say dose-optimisation and longer-term studies are still needed.
Safety Data in Research: What Studies Report
Published safety data for BPC-157 comes almost entirely from animals, where a 2020 toxicology study found no serious toxicity across four species. Human safety data is limited to a two-person pilot. Tolerability data for thymosin beta-4 exists, but it covers the full protein and doesn’t transfer to the TB-500 fragment.
BPC-157: animal toxicity findings
Xu et al. (2020), published in Regulatory Toxicology and Pharmacology, tested BPC-157 in mice, rats, rabbits and dogs. Single-dose testing showed no test-related effects. Local irritation was mild, and the team found no genetic or embryo-fetal toxicity. The authors concluded BPC-157 “did not cause any serious toxicity in mice, rats, rabbits and dogs.”
Blood-chemistry and hormone markers in animal studies
In the Xu repeated-dose dog study, the only blood-chemistry change reported was lower creatinine at the highest dose. It returned to normal within two weeks after the study period ended. The authors reported no other abnormal changes against the control group. On hormones, the only published finding is in vitro: BPC-157 raised growth-hormone receptor levels in rat tendon cells (Chang et al., 2014). As of October 2026, we found no published study that measured BPC-157’s effect on testosterone.
Thymosin beta-4 tolerability data, which apply to the full protein and not to TB-500
A 2021 phase 1 trial gave recombinant human Tβ4 to 54 healthy volunteers in single-dose groups and 30 in multiple-dose groups. The authors reported “no dose-limiting toxicities or serious adverse events”, with mild to moderate side effects (Wang et al., Journal of Cellular and Molecular Medicine, see References). The material tested was the 43-residue protein.
The absence of human safety datasets
The human safety record for BPC-157 is one 2025 pilot with two participants and no control group (Lee and Burgess, see References). The TB-500 fragment has no published human safety study. Short-term tolerability in two people can’t reveal rare or long-term effects.
BPC-157 and TB-500 Blend (“Wolverine Stack or Blend”): What Research Shows
The “Wolverine blend” or stack is an online nickname for BPC-157 and TB-500 combined. One published study has tested the combination. In a 2026 rat Achilles tendon model, the blend gave no additional benefit over either peptide alone. There are no human combination studies, and there’s no published evidence of synergy.
Why the two are paired in research discussions
The pairing logic is complementary biology: BPC-157 is linked to angiogenesis, while TB-500 is linked to cell movement. Put those together and you get a neat two-angle story. Our guide to peptide stacks explains why combination designs need far more controls than single-compound work.
One published combination study so far
Biçer et al. (2026) randomised 32 male rats in a standardised surgical Achilles tendon model into four groups of eight: control, BPC-157, TB-500, and both combined. After four weeks, the authors wrote that the combined treatment “did not confer additional benefits compared to either agent alone.” They suggest both peptides may act on the same downstream pathways, and they flag that idea as untested. It’s one species, one tissue and one time point, so treat it as a first data point.
Research-design considerations: confounding, controls, and documentation for each material
The Biçer design is the template: a four-arm layout with each compound alone, both together, and a control. Without the single-compound arms, you can’t tell which peptide drove a result. Our BPC-157 + TB-500 20mg research pen supports the combined arm. Run the single arms with the individual materials, and log the lot number and COA for each one.
Figure 3: Pairing two compounds multiplies the variables you have to control.
Are BPC-157 and TB-500 Legal in the UK?
BPC-157 and TB-500 are unlicensed in the UK. Neither holds a marketing authorisation from the MHRA, and neither is approved by the US FDA. Under regulation 46 of the Human Medicines Regulations 2012, selling an unauthorised medicinal product is an offence, so UK suppliers sell them strictly for laboratory research.
The wording in the Human Medicines Regulations 2012 is direct: “A person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product.” A product can count as a medicine because of how it’s presented, so the way a peptide is described matters as much as what it is. That’s why research suppliers avoid health claims and label every product for research use only. In practice, that means product pages carry no dosing or usage instructions, and the material is described as a laboratory reagent for analytical and scientific work.
This status is correct as of 15 October 2026. Regulators can change it, so check MHRA guidance before relying on it. For a fuller breakdown, read our guide on whether peptides are legal in the UK.
Quality Checks Before Comparing Peptide Materials
A fair comparison starts with confirming what each material actually is. Check three things for every batch: identity (sequence and mass), the batch-specific Certificate of Analysis, and storage records. A product name on a label confirms none of these.
Verify compound identity
Match the sequence, molecular mass, analytical identity method and lot number to the supplier’s specification. For TB-500, confirm the stated fragment is Ac-LKKTETQ, since “TB-500” is used loosely across the market.
Read the Certificate of Analysis
A useful COA shows an HPLC purity result with its chromatogram, an identity method, a lot number matching your unit, the test date and specification limits. A batch-specific report describes the material you hold; a generic sample COA describes someone else’s. Our materials are typically ≥98% HPLC-verified, and you can check each batch’s documentation by scanning the QR code or entering the batch number. See how this works on our quality and batch verification page.
Storage and handling documentation
Follow the supplier’s batch guidance over generic online advice. Our guidance is a cool, stable environment, typically −20 °C for long-term storage, away from heat and direct light, with handling kept to a minimum.
Format is a separate question from quality. A pre-filled research pen and a lyophilised vial can hold the same peptide, and neither format proves purity or identity. Our peptide pen vs vial guide covers the handling differences.
Figure 4: Pen and vial formats both need batch documentation.
BPC-157 and TB-500 in Competitive Sport
Both are prohibited at all times, in and out of competition. The WADA 2026 Prohibited List, in force since 1 January 2026, names BPC-157 under S0 (non-approved substances). It lists “Thymosin-ß4 and its derivatives e.g. TB-500” under S2, peptide hormones and growth factors. S0 also catches any substance without current government approval for human therapeutic use, so peptides missing from the named examples can still be prohibited.
Frequently Asked Questions
BPC-157 is a 15-amino-acid synthetic peptide derived from a larger natural protein and studied mainly in angiogenesis and tendon models. TB-500 is a seven-residue fragment of thymosin beta-4 studied for actin regulation and cell migration. They differ in size, origin and evidence base, and both rely mostly on animal research.
No. Thymosin beta-4 is a natural 43-amino-acid protein. TB-500 is a synthetic fragment, Ac-LKKTETQ, covering residues 17 to 23. Human trials of thymosin beta-4 used the full protein, so their results can’t be applied directly to TB-500. Published TB-500 fragment data so far comes from animal studies.
BPC-157 has more published studies: a 2025 HSS Journal review counted 36, of which 35 were preclinical. TB-500 has fewer fragment-specific papers, though its parent protein has human trials. In the only head-to-head rat study, published in 2026, TB-500 alone showed a significant gain in tendon strength over controls.
Very little. The 2025 HSS Journal review found one clinical study, a retrospective chart review of 12 people, and reported no clinical safety data. A separate 2025 pilot followed two people with no control group. No controlled human efficacy trial of BPC-157 has been published.
The “Wolverine stack” is an online nickname for BPC-157 and TB-500 used together. One published study has tested the pair: a 2026 rat Achilles tendon study found the combination gave no additional benefit over either peptide alone. No human combination studies exist, and synergy remains unproven.
In a 2020 animal toxicology study, the only blood-chemistry change reported in dogs was lower creatinine at the top dose, which reversed within two weeks. No other abnormal changes were reported. The only hormone-related finding is a 2014 cell study showing higher growth-hormone receptor levels. No published study has measured testosterone.
They’re unlicensed medicines in the UK, with no MHRA marketing authorisation and no FDA approval in the US. Regulation 46 of the Human Medicines Regulations 2012 bars selling unauthorised medicinal products, so UK suppliers sell them for laboratory research only, without health claims. This status was accurate as of October 2026.
Yes. The WADA 2026 Prohibited List bans both at all times. BPC-157 is named under S0, non-approved substances, and thymosin beta-4 and its derivatives, including TB-500, are listed under S2, peptide hormones and growth factors. The current list took effect on 1 January 2026.
References and Editorial Review
This guide relies on primary sources:
- Vasireddi N, et al. HSS Journal, 2025. Systematic review of BPC-157 literature (PMID 40756949).
- Biçer O, et al. Joint Dis Relat Surg, 2026;37(3):822-837. BPC-157 and TB-500 in a rat Achilles tendon model (DOI 10.52312/jdrs.2026.2951).
- Xu C, et al. Regulatory Toxicology and Pharmacology, 2020. Preclinical safety evaluation of BPC-157 (PMID 32334036).
- Chang CH, et al. Molecules, 2014. BPC-157 and growth-hormone receptor expression in rat tendon fibroblasts (PMC6271067).
- Wang X, et al. Journal of Cellular and Molecular Medicine, 2021. Phase 1 study of recombinant human thymosin β4 in healthy volunteers (PMC8419156).
- Lee E, Burgess K. 2025. BPC-157 pilot safety study, two participants (PMID 40131143).
- ClinicalTrials.gov. Thymosin beta-4 phase 2 trial (NCT00311766).
- WADA Prohibited List 2026 and Human Medicines Regulations 2012, regulation 46.
This article does not provide medical or veterinary guidance. All compounds discussed are for laboratory research use only. See our research use notice.